Molecular markers of anti-malarial drug resistance in Lahj Governorate, Yemen: Baseline data and implications

Malaria Journal

Volumn 10, Issue , 2011, Pages

  Mubjer, Reem A ^a   Adeel, Ahmed A ^b   Chance, Michael L ^c   Hassan, Amir A ^c  

^a Aden University   (Yemen)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; MOLECULAR MARKER; PLASMODIUM FALCIPARUM CHLOROQUINE RESISTANCE TRANSPORTER; PYRIMETHAMINE PLUS SULFADOXINE; UNCLASSIFIED DRUG; ANTIMALARIAL AGENT; CARRIER PROTEIN; PFCRT PROTEIN, PLASMODIUM FALCIPARUM; PROTOZOAL PROTEIN; PYRIMETHAMINE; SULFADOXINE; SULFADOXINE-PYRIMETHAMINE;

ADOLESCENT; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CHILD; DNA SEQUENCE; DRUG TREATMENT FAILURE; EXON; GENE AMPLIFICATION; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; NONHUMAN; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; SCHOOL CHILD; THERAPY EFFECT; YEMEN; ADULT; DRUG COMBINATION; DRUG EFFECT; DRUG RESISTANCE; DRUG SENSITIVITY; GENETIC MARKER; GENETIC POLYMORPHISM; GENETICS; INFANT; METHODOLOGY; PARASITOLOGY;

ADOLESCENT; ADULT; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; DIHYDROPTEROATE SYNTHASE; DRUG COMBINATIONS; DRUG RESISTANCE; GENETIC MARKERS; HUMANS; INFANT; MALARIA, FALCIPARUM; MEMBRANE TRANSPORT PROTEINS; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; POLYMORPHISM, GENETIC; PROTOZOAN PROTEINS; PYRIMETHAMINE; SEQUENCE ANALYSIS, DNA; SULFADOXINE; TETRAHYDROFOLATE DEHYDROGENASE; YEMEN; YOUNG ADULT;

EID: 80051790866     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-10-245     Document Type: Article

References (53)

1. WHO, World Malaria report 2010 http://www.who.int/malaria/publications/ country-profiles/profile-yem-en.pdf
2. WHO, Chemotherapy of malaria and resistance to antimalarials Geneva, World Health Organization, 1973 (WHO Technical Report Series, No. 529)
3. Report on the Intercountry Workshop on Monitoring Therapeutic Efficacy of Antimalarial Drugs, Annex 5: Main results of monitoring drug resistance of falciparum malaria by country. Sana'a, Republic of Yemen WHO-EM/MAL/281/E/L 2002 21 25 http://whqlibdoc.who.int/emro/2002/WHO-EM-MAL-281-E-L.pdf accessed 24 February 2011 21863134
4. Berga DK, Assignment report on monitoring therapeutic efficacy of chloroquine for treatment of uncomplicated falciparum malaria in republic of Yemen 21 December 1998-18 January 1999 Accessed 2March 2011: http://www.emro.who.int/rbm/countryreports/yemen/YEM.doc
5. WHO, Monitoring antimalarial drug resistance Report of WHO Consultation, Geneva, Switzerland, 3-5 December 2001. WHO monographs WHO/CDS/CSR/EPH/2002.7 and HO/CDS/RBM/2002.29
6. Chloroquine-resistant malaria. Wellems T, Plowe C, J Infect Dis 2001 184 770 776 10.1086/322858 11517439 (Pubitemid 32826429)
7. Epidemiology of drug-resistant malaria. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR, Lancet Infect Dis 2002 2 209 218 10.1016/S1473-3099(02)00239-6 11937421 (Pubitemid 34464751)
8. Antimalarial drug resistance. White NJ, J Clin Invest 2004 113 1084 1092 15085184 (Pubitemid 38544090)
9. Genetic and biochemical aspects of drug resistance in malaria parasites. Hayton K, Su XZ, Curr Drug Targets Infect Disord 2004 4 1 10 15032630 (Pubitemid 38404692)
10. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN, Djimdé AA, Kouriba B, Taylor TE, Plowe CV, J Infect Dis 2003 187 1870 1875 10.1086/375419 12792863 (Pubitemid 36724485)
11. Alternative mutations at position 76 of the vacuolar transmembrane protein PfCRT are associated with chloroquine resistance and unique stereospecific quinine and quinidine responses in Plasmodium falciparum. Cooper RA, Ferdig MT, Su XZ, Ursos LM, Mu J, Fujioka H, Fidock DA, Roepe PD, Wellems TE, Mol Pharmacol 2002 61 35 42 10.1124/mol.61.1.35 11752204 (Pubitemid 34049510)
12. Pfcrt is more than the Plasmodium falciparum chloroquine resistance gene: a functional and evolutionary perspective. Cooper RA, Hartwig CL, Ferdig MT, Acta Trop 2005 94 170 180 15866507 (Pubitemid 40720324)
13. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Picot S, Olliaro P, de Monbrison F, Bienvenu AL, Price RN, Ringwald P, Malar J 2009 8 89 10.1186/1475-2875-8-89 19413906
14. Molecular basis of in vivo resistance to sulfadoxine-pyrimethamine in African adult patients infected with Plasmodium falciparum malaria parasites. Basco LK, Tahar R, Ringwald P, Antimicrob Agents Chemother 1998 42 1811 1844 9661026
15. Amino acid changes inked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Cowman AF, Morry MJ, Biggs BA, Cross GA, Foote SJ, Proc Natl Acad Sci USA 1988 85 9109 9113 10.1073/pnas.85.23.9109 3057499 (Pubitemid 19001849)
16. Association between antifol resistance in vitro and DHFR gene point mutation in Plasmodium falciparum isolates. de Pecoulas PE, Basco LK, Le Bras J, Mazabraud A, Trans R Soc Trop Med Hyg 1996 90 181 182 10.1016/S0035-9203(96) 90130-3 8761584 (Pubitemid 26141092)
17. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE, Am J Trop Med Hyg 1995 52 565 568 7611566
18. Molecular markers for failure of sulfadoxinepyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV, J Infect Dis 2002 185 380 388 10.1086/338566 11807721 (Pubitemid 34107252)
19. World Antimalarial Resistance Network (WARN). III: Molecular markers for drug resistant malaria. Plowe CV, Roper C, Barnwell JW, Happi CT, Joshi HH, Mbacham W, Meshnick SR, Mugittu K, Naidoo Inbarani, Price RN, Robert Shafer W, Sibley CH, Sutherland CJ, Zimmerman P, Rosenthal PJ, Malar J 2007 6 121 10.1186/1475-2875-6-121 17822535 (Pubitemid 47566322)
20. A molecular marker for chloroquine-resistant falciparum malaria. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV, Coulibaly D, N Engl J Med 2001 344 257 263 10.1056/NEJM200101253440403 11172152 (Pubitemid 32108530)
21. Johnson DJ, Studies on the molecular basis of chloroquine resistance inPlasmodium falciparum Ph.D. thesis 2003, University of Liverpool, UK
22. Plasmodium falciparum: detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. Duraisingh MT, Curtis J, Warhurst DC, Exp Parasitol 1998 89 1 8 10.1006/expr.1998.4274 9603482 (Pubitemid 28377366)
23. Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. Snounou G, Zhu X, Siripoon N, Jarra W, Thaithong S, Brown KN, Viriyakosol S, Trans R Soc Trop Med Hyg 1999 93 369 374 10.1016/S0035-9203(99)90120-7 10674079 (Pubitemid 29405860)
24. Diversity of Plasmodium falciparum clones infecting children living in a holoendemic area in north-eastern Tanzania. Magesa SM, Mdira KY, Babiker HA, Alifrangis M, Farnert A, Simonsen PE, Bygbjerg IC, Walliker D, Jakobsen PH, Acta Trop 2002 84 83 92 10.1016/S0001-706X(02)00179-1 12429425 (Pubitemid 35335759)
25. Multivariate analysis. A practical guide for clinicians. Katz MH, Cambridge University Press 1999
26. Predictors of chloroquine treatment failure in children and adults with falciparum malaria in Kampala, Uganda. Dorsey G, Kamya MR, Ndeezi G, Babirye JN, Phares CR, Olson JE, Katabira ET, Rosenthal PJ, Am J Trop Med Hyg 2000 62 686 692 11304055 (Pubitemid 32281486)
27. Efficacy of chloroquine in the treatment of uncomplicated, Plasmodium falciparum malaria in northern Ghana. Ehrhardt S, Mockenhaupt FP, Agana-Nsiire P, Mathieu A, Anemana SD, Stark K, Otchwemah RN, Bienzle U, Ann Trop Med Parasitol 2002 96 239 247 10.1179/000349802125000772 12061971 (Pubitemid 34548045)
28. Sentinel posts for monitoring therapeutic efficacy of antimalarial drugs against Plasmodium falciparum in the Sudan. Abdel-Hameed AA, El-Jak IE, Faragalla IA, African Journal of Medicine and Medical Sciences 2001 30 suppl 1 5 14513931
29. Predictors of antimalarial treatment failure in an area of unstable malaria transmission in eastern Sudan. Adam I, Elmardi KA, Malik EM, Trans R Soc Trop Med Hyg 2009 103 21 4 10.1016/j.trstmh.2008.07.005 18718621
30. The roles of the pfcrt 76T and pfmdr1 86Y mutations, immunity and the initial level of parasitaemia, in predicting the outcome of chloroquine treatment in two areas with different transmission intensities. Khalil IF, Alifrangis M, Tarimo DS, Staalsø T, Satti GM, Theander TG, Rønn AM, Bygbjerg IC, Ann Trop Med Parasitol 2005 99 441 448 10.1179/136485905X46441 16004703 (Pubitemid 40992388)
31. Role of the pfcrt codon 76 mutation as a molecular marker for population-based surveillance of chloroquine (CQ)-resistant Plasmodium falciparum malaria in Ugandan sentinel sites with high CQ resistance. Talisuna AO, Kyosiimire-Lugemwa J, Langi P, Mutabingwa TK, Watkins W, Van Marck E, Egwang T, D'Alessandro U, Trans R Soc Trop Med Hyg 2002 96 551 556 10.1016/S0035-9203(02)90439-6 12474488 (Pubitemid 35386234)
32. The Lys-76-Thr mutation in PfCRT and chloroquine resistance in Plasmodium falciparum isolates from Uganda. Kyosiimire-Lugemwa J, Nalunkuma-Kazibwe AJ, Mujuzi G, Mulindwa H, Talisuna A, Egwang TG, Trans R Soc Trop Med Hyg 2002 96 91 95 10.1016/S0035-9203(02)90252-X 11926004 (Pubitemid 34846542)
33. Analysis of gene mutations involved in chloroquine resistance in Plasmodium falciparum parasites isolated from patients in the southwest of Saudi Arabia. Bin Dajem SM, Al-Qahtani A, Ann Saudi Medicine 2010 30 187 192 10.4103/0256-4947.62826
34. High-level chloroquine resistance in Sudanese isolates of Plasmodium falciparum is associated with mutations in the chloroquine resistance transporter gene pfcrt and the multidrug resistance gene pfmdr1. Babiker HA, Pringle SJ, Abdel-Muhsin A, Mackinnon M, Hunt P, Walliker D, J Infect Dis 2001 183 1535 1538 10.1086/320195 11319692 (Pubitemid 32417707)
35. Plasmodium falciparum malaria in Laos: chloroquine treatment outcome and predictive value of molecular markers. Pillai DR, Labbe AC, Vanisaveth V, Hongvangthong B, Pomphida S, Inkathone S, Zhong K, Kain KC, J Infect Dis 2001 183 789 795 10.1086/318836 11181156 (Pubitemid 32171754)
36. Treatment of malaria outside the formal health services. Foster S, J Trop Med Hyg 1995 98 29 34 7861477
37. Treatment seeking for malaria: a review of recent research. McCombie SC, Soc Sci Med 1996 43 933 945 10.1016/0277-9536(95)00446-7 8888463 (Pubitemid 26306536)
38. Clustering of malaria treatment failure (TF) in Daraweesh: hints for host genetic susceptibility to TF with emphasis on immune-modulating SNPs. Giha HA, ElGhazali G, Nasr A, Iriemenam NC, Berzins K, Troye-Blomberg M, Theander TG, Arnot D, Infect Genet Evol 2010 10 481 486 10.1016/j.meegid.2010.02.013 20215002
39. Monitoring antimalarial drug resistance: making the most of the tools at hand. Plowe C, J Exp Biol 2003 206 3745 3752 10.1242/jeb.00658 14506209 (Pubitemid 37365456)
40. Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. Djimde A, Doumbo OK, Steketee RW, Plowe CV, Lancet 2001 358 890 891 10.1016/S0140-6736(01)06040-8 11567708 (Pubitemid 32900575)
41. Children in Burkina Faso who are protected by insecticide-treated materials are able to clear drug resistant parasites better than unprotected children. Diallo DA, Sutherland C, Nebie I, Ord R, IIboudo-Sanogo E, Greenwood BM, Cousens SN, J Infect Dis 2007 196 138 44 10.1086/518252 17538894 (Pubitemid 46982748)
42. Heterologous expression of active thymidylate synthase-dihydrofolate reductase from Plasmodium falciparum. Sirawaraporn W, Sirawaraporn R, Cowman AF, Yuthavong Y, Santi DV, Biochemistry 1990 29 10779 10785 10.1021/bi00500a009 2176883
43. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Peterson DS, Milhous WK, Wellems TE, Proc Natl Acad Sci USA 1990 87 3018 22 10.1073/pnas.87.8.3018 2183222
44. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine- sulfadoxine use and resistance. Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC, Watkins WM, Winstanley PA, Estrada-Franco JG, Mollinedo RE, Avila JC, Cespedes JL, Carter D, Doumbo OK, J Infect Dis 1997 176 1590 1596 10.1086/514159 9395372 (Pubitemid 27518161)
45. Pyrimethamine/sulfadoxine combination in the treatment of uncomplicated falciparum malaria: relation between dihydropteroate synthase/dihydrofolate reductase genotypes, sulfadoxine plasma levels, and treatment outcome. Khalil I, Alifrangis M, Ronn AM, Gabar HA, Jelinek T, Satti GM, Bygbjerg IC, Am J Trop Med Hyg 2002 67 225 229 12408659 (Pubitemid 35178344)
46. Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. Wang P, Lee CS, Bayoumi R, Djimde A, Doumbo O, Swedberg G, Dao LD, Mshinda H, Tanner M, Watkins WM, Sims PF, Hyde JE, Mol Biochem Parasitol 1997 89 161 177 10.1016/S0166-6851(97)00114-X 9364963 (Pubitemid 27435090)
47. Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure? Omar SA, Adagu IS, Warhurst DC, Trans R Soc Trop Med Hyg 2001 95 315 319 10.1016/S0035-9203(01)90250-0 11491006 (Pubitemid 33713086)
48. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Nzila AM, Mberu EK, Sulo J, Dayo H, Winstanley PA, Sibley CH, Watkins WM, Antimicrob Agents Chemother 2000 44 991 996 10.1128/AAC.44.4.991-996.2000 10722502 (Pubitemid 30165281)
49. A trial of proguanil-dapsone in comparison with sulfadoxine-pyrimethamine for the clearance of Plasmodium falciparum infections in Tanzania. Mutabingwa TK, Maxwell CA, Sia IG, Msuya FH, Mkongewa S, Vannithone S, Curtis J, Curtis CF, Trans R Soc Trop Med Hyg 2001 95 433 438 10.1016/S0035-9203(01)90207-X 11579891 (Pubitemid 33713114)
50. dhfr and dhps genotype and sulphadoxine-pyrimethamine treatment failure in children with falciparum malaria in the Democratic Republic of Congo. Alker AP, Kazadi WM, Kutelemeni AK, Bloland PB, Tshefu AK, Meshnick SR, Trop Med Int Health 2008 13 1384 1391 10.1111/j.1365-3156.2008.02150.x 19055622 (Pubitemid 352672614)
51. Population-based validation of dihydrofolate reductase gene mutations for the prediction of sulfadoxine-pyrimethamine resistance in Uganda. Talisuna AO, Langi P, Mutabingwa TK, Watkins W, Van Marck E, Egwang TG, D'Alessandro U, Trans R Soc Trop Med Hyg 2003 97 338 342 10.1016/S0035-9203(03)90163-5 15228255 (Pubitemid 39185893)
52. Frequency distribution of antimalarial drug resistance alleles among Plasmodium falciparum isolates from Gezira State, central Sudan, and Gedarif State, eastern Sudan. Menegon M, Talha AA, Carlo Severini, Elbushra SM, Mohamedani AA, Malik EM, Mohamed TA, Wernsdorfer WH, Majori G, Nour BYM, Am J Trop Med Hyg 2010 83 250 257 10.4269/ajtmh.2010.09-0514 20682863
53. Principal role of dihydropteroate synthase mutations in mediating resistance to sulfadoxine-pyrimethamine in single-drug and combination therapy of uncomplicated malaria in Uganda. Dorsey G, Dokomajilar C, Kiggundu M, Staedke SG, Kamya MR, Rosenthal PJ, Am J Trop Med Hyg 2004 71 758 763 15642967 (Pubitemid 40075626)